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Neuroinflammation plays a key role in the initiation and progression of neurodegeneration in Alzheimer’s disease (AD).
Chronic neuroinflammation results in diminished synaptic plasticity and loss of GluN1 N-methyl-D-aspartate (NMDA)
receptors in the hippocampus, leading to the cognitive deficits that are the most common symptoms of AD. Therefore,
it is suggested that chronic inflammation may alter expression levels of GluN2A and GluN2B subunits of NMDA
receptors and associated intracellular signalling. Chronic neuroinflammation was induced by chronic infusion of
lipopolysaccharide (LPS) into the fourth ventricle in Fischer-344 rats. The status of hippocampus-dependent memory
was evaluated in control rats and rats chronically infused with LPS. Microglial activation in the hippocampus was
examined using immunohistochemical staining. Western blot analysis was used to measure membrane levels of
GluN2A and GluN2B subunits of NMDA receptors and mitogen-activated protein kinase (MAPK) in the hippocampi
of these rats, and immunofluorescent double labeling was used to assess the cellular location of MAPK. Microglial
activation was observed in the hippocampi of rats that showed memory impairments with chronic LPS infusion.
Chronic LPS infusion reduced the levels of GluN2A and GluN2B and increased the levels of phosphorylated MAPKs in
the hippocampus. MAPK-positive immunoreactivity was observed mostly in the neurons and also in non-neuronal cells.
Reductions in GluN2A and GluN2B subunits of NMDA receptors coupled with altered MAPK signaling, in response to
inflammatory stimuli may be related to the cognitive deficits observed in AD.
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Neuroinflammation plays a key role in the initiation and
progression of neurodegeneration in Alzheimer’s disease
(AD) [1-5]. In vivo measurement of activated microglia
using brain imaging suggests that inflammation is an early
event in the pathogenesis of the disease [6,7]. A series of
animal experiments with chronic lipopolysaccharide (LPS)
infusion into the brain has demonstrated that inflammation* Correspondence: jshan06@konkuk.ac.kr
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unless otherwise stated.leads to cognitive deficits, which are the most common
symptom of AD [8,9].
It has also been demonstrated that brain inflammation
leads to a decrease in the number of GluN1 N-methyl-D-
aspartate receptors (NMDARs) within the dentate gyrus
(DG) and cornu ammonis 3 (CA3) hippocampal areas,
without any loss of neurons [10]. On the basis of the asso-
ciation of GluN1 and synaptic plasticity [11], electro-
physiological studies were performed to examine the
effects of chronic LPS infusion on long-term potentiation
(LTP) and long-term depression (LTD) in the hippocam-
pus [12-14]. LPS infusion has been shown to impair LTP
in perforant path-granular cell synapses [12]. In addition,
voltage-dependent calcium channel dependent-LTP and. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tenuated [13] as well as LTD has been impaired [14] in
Schaffer collateral-cornu ammonis 1 (CA1) synapses in
the hippocampus of rats chronically infused with LPS.
NMDARs are tetrameric protein complexes composed
of GluN1 subunits with at least one type of GluN2 sub-
unit. As stated above, chronic LPS infusion impairs synap-
tic plasticity and reduces the number of GluN1 NMDARs.
Therefore, it is predicted that chronic LPS infusion would
reduce the expression levels of GluN2A and GluN2B sub-
units of NMDARs, which are essential mediators of synap-
tic plasticity [15]. Studies using primary cultured neurons
have reported that in mature neurons, GluN2B is associ-
ated with inhibition, rather than activation, of extracellular
signal-regulated kinases 1/2 (Erk1/2) that are the best
studied mitogen-activated protein kinases (MAPKs) [16].
It has also been shown that the phosphorylated levels of
p38, a subfamily of MAPKs, depend on the concentration
of experimentally applied NMDA and NMDAR subtype
composition or localization [17].
In addition, in neurological disorders such as AD, it is
well known that MAPKs are crucial for the regulation of
microglia-mediated inflammation [18] and are key regula-
tors of tau phosphorylation and plaque formation, which
can eventually lead to dementia and AD [19]. Our previ-
ous study reported increased levels of phosphorylated
Erk1/2 (p-Erk1/2) in the hippocampus following micro-
glial activation by chronic LPS infusion [20]. The present
experiment was conducted to evaluate the effects of
chronic LPS infusion on the expression levels of GluN2A
and GluN2B subunits of NMDARs and its associated Erk
and p38 signaling. In the present study, membrane levels
of GluN2A and GluN2B were reduced in the hippocampi
of Fischer-344 rats that exhibited neuroinflammatory re-
sponses and memory impairments induced by chronic
LPS infusion into the 4th ventricle. In addition, levels of
p-Erk1/2 and phosphorylated p38 (p-p38) were increased
in the hippocampus of chronically LPS-infused rats, and
these immunoreactivities were observed mostly in neurons
and also in non-neuronal cells in the hippocampi of LPS-
infused rats.
Results and discussion
Spatial memory impairments in chronically LPS-infused rats
As reported previously, LPS-infused rats showed impair-
ments of spatial memory [12,13]. The average search error
in the spatial learning task during a 5- training trial block
was used to assess spatial memory in the rats. The artificial
cerebrospinal fluid (aCSF) -infused rats became proficient
at locating the submerged platform during the training
trials. Compared with the aCSF-infused rats, the LPS-
infused rats showed less improvement over the course of
the training, evidenced by that acquisition slope in the
spatial learning differed in two groups (F (1, 21) = 4.67, p <0.05, Figure 1A). The one-way analysis of variance
(ANOVA) with repeated variable for search error showed
that the between-group effects (aCSF vs. LPS) were signifi-
cant (F (1, 21) = 5.47, p < 0.05) and the training effects
were also significant (F (3, 63) = 47.81, p < 0.001). There
were no interaction effects of group and training (F (3,
63) = 0.31, no significance [ns]).
The percentage of time spent in a target area contain-
ing the platform and 5 times of the platform diameter
was measured during the 30 s probe trial (Figure 1B).
The repeated ANOVA showed that the between-group
effects were significant (F (1, 21) = 4.80, p < 0.05), the
spatial bias over the course of training was significantly
increased (F (3, 63) = 18.41, p < 0.01), and the interaction
effects of the group and probe were significant (F (3, 63) =
4.20, p < 0.01). A post-hoc analysis revealed spatial bias in
the probe trial conducted 24 h after 3 blocks of training
trials (15 trials) was higher in the aCSF-infused rats than
in the LPS-infused rats (p < 0.05). There were no differ-
ences in swimming speeds between the 2 groups of rats
(data not shown).
Activated microglia in the hippocampus of chronically
LPS-infused rats
The locations of the cannula tips were verified while sec-
tioning the brain portions containing the 4th ventricle
using the microtome. All cannula tips were located in the
4th ventricle. Tissues from 17 rats were used for immuno-
histological observations and those from the remaining 6
rats for western blot analyses.
Among brain cells, ionized calcium binding adaptor mol-
ecule 1 (Iba-1) expression is restricted in ramified micro-
glia/macrophage [21] and its expression is up-regulated in
activated microglial/macrophage [22] following exposure
to an inflammatory stimulus or an inflammation-induced
challenge such as facial nerve axotomy [23]. Compared to
the aCSF-infused rats, the LPS-infused rats showed more
microglial cells in the hippocampal CA1, CA3, and DG
areas (Additional file 1: Figure S1). The repeated ANOVA
showed that the between-group effects (aCSF vs. LPS) were
significant (F (1, 6) = 6.50, p < 0.05), whereas the regional
differences (CA1, CA3, and DG) effects were not significant
(F (2, 12) = 3.34, ns). There were no interaction effects of
group and region (F (2, 12) = 1.26, ns).
In the present study, we also observed activated microglia
with immunostaining for OX-6 directed against the Class II
major histocompatibility complex. Activated microglial cells
were highly distributed in hippocampal CA3 and DG areas
in the LPS-infused rats (Additional file 1: Figure S1). In
contrast, aCSF-infused rats had no activated microglial
cells. The OX-6-positive microglial cells within the
hippocampus were counted in drawings of identical sec-
tions from each rat. The repeated ANOVA showed that
the between-group effects (aCSF vs. LPS) were significant
Figure 1 Performance of aCSF- and LPS-infused rats in the spatial version of a Morris water maze. (A) Search error in finding a hidden
platform in a spatial learning task during 5 training trial blocks. The artificial cerebrospinal fluid (aCSF)-infused rats (labeled as aCSF) became proficient
at locating the submerged platform during training. The lipopolysaccharide (LPS)-infused rats (labeled as LPS) showed less improvement over the
course of training when compared with the aCSF-infused rats (*, p < 0.05). (B) The percentage of time spent in the target annulus which was 5 times of
the platform size, during the 30 s probe trial. The aCSF-infused rats spent more time in the target area than the LPS-infused rats, and this was
statistically significant at the third probe trial (*, p < 0.05).
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CA3, and DG) effects and interaction effects of group and
region were significant (F (2, 12) ≥ 12.68, p < 0.05).Reduction of GluN2A and GluN2B subunits of NMDARs in
the hippocampus of chronically LPS-infused rats
The expression levels of GluN2A and GluN2B subunits
of NMDARs in the membrane fraction of the hippocam-
pus were measured using western blot. The membrane ex-
pression levels of GluN2A were slightly decreased in the
hippocampi of the LPS-infused rats than in those of the
aCSF-infused rats (F (1, 10) = 6.50, p < 0.05) (Figure 2). In
addition, the membrane expression levels of GluN2B were
much decreased in the hippocampi of the LPS-infused rats
than in those of the aCSF-infused rats (F (1, 10) = 11.63,
p < 0.05).Figure 2 Membrane levels of GluN2A and GluN2B subunits of NMDAR
(A) Representative western blot of GluN2A, GluN2B, and actin. (B, C) Memb
of the LPS-infused rats than in those of the aCSF-infused rats (*, p < 0.05).Increased p-Erk1/2 and p-p38 in the hippocampus of
chronically LPS-infused rats
The levels of hippocampal p-Erk1/2 over p-Erk1/2 and
p-p38 over p38 measured using a western blot were
highly increased in the hippocampi of the LPS-infused
rats than in those of the aCSF-infused rats (p-Erk1/2
(F (1, 4) = 8.55, p < 0.05; p-p38 (F (1, 4) = 13.48, p < 0.05)
(Figure 3). The levels of hippocampal Erk1/2 and p38
did not differ significantly between the LPS- and aCSF-
infused rats (aCSF: Erk1/2/actin [1.37 ± 0.032], p38/actin
[1.47 ± 0.094]; LPS: Erk1/2/actin [1.37 ± 0.037], p38/actin
[1.59 ± 0.0270]).
Cellular distribution of p-Erk1/2 and p-p38 immunoreac-
tivity in the hippocampus of chronically LPS-infused rats
To determine the cellular types that express p-Erk1/2
and p-p38 in the hippocampus of the LPS-infused rats,s in the hippocampi of aCSF- and LPS-infused rats.
rane levels of GluN2A and GluN2B were decreased in the hippocampi
Figure 3 Levels of hippocampal phosphorylated extracellular signal-regulated kinase 1/2 and phosphorylated p38 in the aCSF- and
LPS-infused rats. (A) Representative western blot of extracellular signal-regulated kinase 1/2 (Erk1/2), phosphorylated Erk1/2 (p-Erk1/2), and actin.
(B) Levels of p-Erk1/2 were higher in the hippocampi of the LPS-infused rats than in that of the aCSF-infused rats. (C) Representative western blot
of p38, phosphorylated p38 (p-p38), and actin. (D) Levels of p-p38 were higher in the hippocampi of LPS-infused rats than in that of the
aCSF-infused rats. *, p < 0.05. The relative expression levels of all proteins were determined by densitometry and normalized to actin.
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aCSF-infused rats and the LPS-infused rats. While p-
Erk1/2 and p-p38 immunoreactivities were weak in the
hippocampus of the aCSF-infused rats, they were strong
in that of the LPS-infused rats. The p-Erk1/2- and p-p38-
positive signals were located in the pyramidal cells in the
hippocampal CA1, CA3, and DG areas (Figures 4 and 5).
Double labeling with p-Erk1/2 and NeuN (Figures 4 and 5)
demonstrated that almost all of p-Erk1/2 positive cells in
the hippocampal CA1, CA3, and DG areas were neurons.
The immunoreactive products were located in the cyto-
plasm and processes of the neurons. On the other hand,
double staining with p-Erk1/2 and CD11b directed against
complement receptor 3 on macrophage and microglia or
anti-glial fibrillary acidic protein (GFAP) expressed in as-
trocytes demonstrated that p-Erk1/2 and p-p38 were
also increased in glial cells. Specifically, no significant
differences between the LPS-infused rats and the aCSF-
infused rats were observed in p-Erk1/2 levels which
were expressed in the CD11b-positive microglia of the
hippocampus (Figure 4D). However, p-Erk1/2 levels of
which were expressed in the GFAP-positive astrocyte
were significantly higher in the hippocampal CA1, CA3,
and DG areas of the LPS-infused rats than those of the
aCSF-infused rats (F (1, 8) ≥ 9.34, p < 0.01; Figure 4E).
And expression levels of p-p38 in the CD11b-positive
microglia of the LPS-infused rats were significantly in-
creased only in the hippocampal CA3 region, compared
with those of the aCSF-infused rats (F (1, 4) = 10.38, p <0.05; Figure 5D). Levels of p-p38 which were expressed
in the GFAP-positive astrocyte of the LPS-infused rats
were significantly increased only in the hippocampal
CA1 region compared with those of the aCSF-infused
rats (F (1, 8) = 11.00, p < 0.01; Figure 5E).
In the present study, rats that received chronic LPS infu-
sion into the 4th ventricle for 28 days showed poor per-
formance on the spatial memory version of the Morris
water maze task. The hippocampus responsible for spatial
memory showed microglial activation, as evidenced by the
increased number of Iba-1- and OX-6- positive cells. These
results have been previously reported in studies using the
same animal model [8,20]. In addition, electrophysiological
experiments measuring synaptic plasticity such LTP and
LTD in the hippocampus of chronically LPS-infused rats
revealed that chronic LPS infusions impaired the induction
of both NMDAR-dependent and NMDAR-independent
LTP as well as NMDAR-dependent LTD in hippocampal
Schaffer collateral-CA1 synapses [13,14].
In addition to impaired synaptic plasticity induced
by chronic LPS infusion [13,14,24], the loss of GluN1
NMDARs was observed in the hippocampus of chronic-
ally LPS-infused rats [10]. Therefore, we predicted that
chronic LPS infusion would decrease levels of GluN2A
and GluN2B subunits of NMDARs and induce alter-
ation of MAPK signaling, such as Erk1/2 and p38, asso-
ciated with these subunits [16,17,25,26]. As predicted,
chronic LPS infusion decreased levels of GluN2A and
GluN2B in the hippocampal membrane fraction and
Figure 4 Confocal photomicrographs of dual staining for p-Erk1/2 and markers of cellular location in the CA1, CA3, and DG of the
aCSF- and LPS-infused rats. Photomicrographs showed the overlap between p-Erk1/2-positive signals and NeuN, a neuronal marker (A), or CD11b, a
microglial marker (B), or GFAP, an astrocyte marker (C). The p-Erk1/2-positive cells were observed mostly in neurons and also in microglia or astrocytes.
No differences between the LPS- and the aCSF-infused rats were observed in p-Erk1/2 levels expressing in the CD11b-positive microglia of the
hippocampus (D). Levels of p-Erk1/2 expressing in the GFAP-positive astrocyte were significantly increased in the hippocampal CA1, CA3, and DG areas
of the LPS-infused rats compared with the aCSF-infused rats (E). *, p < 0.01.
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with GluN2A and GluN2B.
Specifically, GluN2A and GluN2B levels of membrane
fraction were much decreased, and phosphorylated Erk1/2
levels were increased in the hippocampus of rats chronic-
ally infused with LPS. The increased phosphorylation of
Erk1/2 associated with decreased levels of GluN2B can be
explained by the findings of a previous study, which dem-
onstrated, using the primary cultured hippocampal cells,
that GluN2B is associated with inhibition rather thanactivation of Ras-Erk1/2 [16]. However, there is a possibil-
ity that in response to chronic LPS infusion, the phosphor-
ylation of Erk1/2 was increased due to reductions of other
NMDA-subtype receptors such as GluN1 and GluN2A or
changes in the other receptor or molecules that have not
been examined so far. Chronic LPS infusion also increased
levels of p-p38 in the hippocampus. It has been reported
that the effects of NMDARs on p38 phosphorylation depend
on the subtype composition or localization [17]. In addition,
the present study examined the cellular localizations of
Figure 5 Confocal photomicrographs of dual staining for p-p38 and markers of cellular location in the CA1, CA3, and DG of the
aCSF- and LPS-infused rats. Photomicrographs showed an overlap between p-p38-positive signals and NeuN, a neuronal marker (A), or CD11b, a
microglial marker (B), or GFAP, an astrocyte marker (C). The p-p38-positive cells were observed mostly in neurons and also in glial cells. Compared
with the aCSF-infused rats, levels of p-p38 expressing in the CD11b-positive microglia were increased only in the hippocampal CA3 region of the
LPS-infused (D; *, p < 0.05) and levels of p-p38 expressing in the GFAP-positive astrocyte were significantly increased only in the hippocampal CA1
region of the LPS-infused rats (E; *, p < 0.01).
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ally infused with the LPS. Immunoreactivities of p-p38
and p-Erk1/2 were mostly observed in neurons of the
hippocampi of chronically LPS-infused rats. However,
levels of p-Erk1/2 signals expressing in the GFAP-
positive astrocytes were significantly higher in chronic-
ally LPS-infused rats than aCSF-infused rats. Levels of
p-p38 signals expressing in the CD11b-positive micro-
glia and levels of p-p38 signals expressing in the GFAP-
positive astrocytes were increased in the hippocampal
CA1 and CA3 area, respectively, in chronically LPS-infused rats compared with aCSF-infused rats. Thus, be-
cause increased MAPK signal was also observed in the
glial cells of the hippocampus with the chronic LPS infu-
sion, it needs further investigation to draw a conclusion
that chronic inflammation causes NMDAR reduction
leading altered MAPK signing in neuron.
Chronic inflammation is a key feature in the pathogen-
esis of neurodegenerative disorders including AD [1].
Classic neuropathological features of AD include amyloid
plaques and neurofibrillary tangles [3]. Clumps of acti-
vated microglia and reactive astrocytes appear in the
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vated in response to exposure to LPS, interferon-γ, or β-
amyloid [27,28]. In adult brain, LPS binds to microglia
through toll-like receptor 4, the LPS receptor [29]. Once
chronically activated, the microglial cells produce a variety
of proinflammatory mediators and potentially neurotoxic
compounds such as interleukin (IL)-1β, IL-6, tumor ne-
crosis factor-α, reactive oxygen species, and nitric oxide
and control neuronal activity dynamically and closely as-
sociated neurons and astrocytes [29]. Under pathological
conditions, these have deleterious effects on neuronal
function [30].
Through a series of animal experiment with chronic
LPS infusion into the 4th ventricle, the sequence of events
from activation of astrocyte and microglia to alterations of
MAPK signaling in the hippocampus has been examined.
Chronic LPS infusion induces the release of inflammatory
cytokines by activated astrocytes and microglia [31]. Sub-
sequently, these cytokines increase the production of other
inflammatory mediators such as prostaglandins [32]. Pros-
taglandins, in turn, induce the release of glutamate from
astrocytes [33,34], resulting in an increase of extracellu-
lar glutamate and the overstimulation of glutamate re-
ceptors that lead to the loss of NMDARs and the
alteration of intracellular signaling such as MAPK in
hippocampal neurons [10].
A growing body of evidence suggests that inflammation
is widely linked with neurodegenerative disorders including
AD. As an experimental animal model of AD and other
neurological disorders associated with neuroinflammation,
we slowly infused LPS into the 4th ventricle of Fischer-344
rats for 28 days to induce chronic inflammation. The rats
with chronic LPS infusion had activated microglia, which
play a role as immune effectors in the central nervous sys-
tem. We also observed high levels of p-p38 and p-Erk1/2
in the hippocampus of rats chronically infused with LPS.
Even though in the present study, MAPK alterations oc-
curred mostly in neurons, we could not rule out the possi-
bility that MAPK alterations would mainly occur in
astrocytes and microglia during chronic inflammatory pro-
cesses, because our follow-up period was only 4 weeks
after the initiation of LPS infusion. The Aβ peptide, one of
the pathologic hallmarks in AD, has been identified in the
MAPK cascade as the major transduction pathway in-
volved in the transcription of inflammatory mediators.
Some studies have reported that β-amyloid fibrils in micro-
glia stimulate rapid, transient activation of p38, resulting in
inflammatory gene expression and upregulation of pro-
inflammatory cytokines [35,36]. Thus, in chronic LPS ani-
mal model, chronically activated microglial cells in which
phosphorylation of MAPKs occurred would produce a var-
iety of proinflammatory mediators, leading to either the
release of extracellular glutamate from glia or the func-
tional loss of glutamate reuptake in glia. The increase ofextracellular glutamate might downregulate the glutamate
receptors associated with MAPK signaling.
Conclusions
Rats chronically infused with LPS showed hippocampus-
dependent spatial memory impairments in the Morris
water maze task and microglial activation in the hippo-
campus. Levels of hippocampal p38 and Erk1/2 phos-
phorylation were higher in LPS-infused rats than in
aCSF-infused rats, and these increases in levels were ob-
served in neurons and in glial cells. Alteration of neur-
onal or glial MAPK intracellular signaling in response
to inflammatory stimuli may be related to the cognitive
deficits observed in AD.
Methods
Animals
Thirty-seven male Fischer-344 rats (SLC Inc., Shizuoka,
Japan) were housed singly in colony rooms with a 12-h
light/dark cycle (lights on at 0700). The rats had free ac-
cess to food and water in a temperature-controlled room
(22°C). The Institutional Animal Care and Use Committee
of Konkuk University approved all protocols described in
the report. The behavioral testing was performed during
the light phase.
Surgery
The rats were anesthetized with isoflurane and placed in
a stereotaxic frame (Kopf Instruments, Tujunga, CA,
USA) fitted with an isoflurane gas anaesthesia system,
and an incisor bar was set at 3.3 mm below the ear bars.
The scalp was incised and retracted, and holes were
drilled at the appropriate locations in the skull with a
dental drill. The coordinates for the 4th ventricle infu-
sions were as follows: 2.5 mm posterior to lambda on
the midline and 7.0 mm ventral to the dura. Either LPS
(Sigma, prepared from Escherichia coli, serotype 055:B5)
or aCSF was chronically infused (0.25 μl/h for 28 days)
through a cannula that was implanted in the 4th ven-
tricle of the brain and attached to an osmotic minipump
placed under the axillary skin (model 2004; Alzet, Palo
Alto, CA, USA,) as described elsewhere [10]. The com-
position of the aCSF (in mM) was 148 NaCl; 3.0 KCl; 1.4
CaCl2 2.H2O; 0.8 MgCl2.6H2O; 0.8 Na2HPO4.7H2O; 0.2
NaH2PO4.H2O; pH 7.4.
Apparatus
The rats were trained in a Morris water maze. The maze
was a round tank, 1.83 m in diameter and 58 cm deep,
filled to a depth of 35.5 cm with tepid (27°C) water that
was made opaque by adding white paint (tempera). A
moveable circular platform, 12 cm in diameter, was lo-
cated 2 cm below the surface of the water. The maze
was surrounded with white curtains on which 3 black
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for providing visual stimuli. A camera located above the
center of the maze relayed images to a videocassette re-
corder and an HVS Image Analysis Computer System
(Hampton, United Kingdom). Data from the water maze
trials were analyzed with software provided by HVS.
Behavioral procedure
In a standardized procedure that required the use of dis-
tal cues in a maze environment, the rats (aCSF, n = 11;
LPS, n = 12) were trained to learn the position of a
camouflaged escape platform [37]. Briefly, the rats were
trained in 2 or 3 trials per day with an intertrial interval
of 60 s, and this was performed for 9 consecutive days.
The location of the platform remained constant and, in
each training trial, the rats swam for 90 s or until they
found the platform. Across the trials, the starting loca-
tion varied among 4 equidistant points around the per-
imeter of the apparatus. A probe trial (every sixth trial)
was conducted 24 h after every fifth training trial to as-
sess the development of spatial bias in the maze: thus,
the entire training procedure included 4 probe trials for
each rat. During these probe trials, the rats swam with
the platform retracted to the bottom of the pool for
30 s. After that, the platform was raised to its normal
position for completion of the trial. At the completion of
the protocol with the hidden platform, all rats were
assessed for cue learning using a visible platform. The
location of this platform varied from trial to trial in a
single session of 6 training trials.
Western blot analysis
Three rats from each group were euthanized by rapid
decapitation after the behavioral experiments. The brains
were removed and the hippocampi were rapidly dis-
sected and frozen at 80°C for protein studies. Membrane
isolation and protein analyses of the GluN2A and
GluN2B subunits of NMDARs were extracted in the fol-
lowing manner: The hippocampi of the rats were dis-
sected and homogenized in cold buffer A containing
250 mM sucrose, 20 mM HEPES (pH 7.5), 50 mM KCl,
2 mM ethyleneglycoltetraacetic acid (EGTA), and prote-
ase inhibitor cocktail (Calbiochem). The lysates were
centrifuged at 800 × g for 10 min to remove the nuclei
and large cell debris, and the supernatants were pooled
and centrifuged at 100,000 × g for 1 h. The membrane
pellet were resuspended in buffer B containing 20 mM
HEPES (pH 7.0), 150 mM KCl, 2 mM EGTA, 1% (w/v)
CHAPSO (Sigma), and protease inhibitor cocktail and
then incubated at 4°C for 1 h with vortexing in every
5 min. The solubilized membranes were centrifuged at
100,000 × g for 1 h, and the supernatants were collected
[38]. Proteins for the analysis of MAPKs and phosphory-
lated form of MAPK were extracted in the followingmanner: Individual tissue samples were weighed and
then homogenized in 500 μl of ice-cold buffer contain-
ing 20 mM tris (hydroxymethyl) aminomethane–HCl
(pH 7.4), 1% Triton-X 100, 1.5 mM EGTA, 40 mM KCl,
5% glycerol, 0.5 mM dithiothreitol, 1 mM NaF, 1 mM
Na3VO4, 1 mM phenylmethylsulfonyl fluoride, and pro-
teinase inhibitor. The homogenates were centrifuged at
18,300 × g for 60 min at 4°C.
The supernatants of the membrane fraction and the ho-
mogenates were obtained from each sample, and aliquots
were taken to determine the total protein concentration
using the Bradford Reagent. The proteins were then sepa-
rated by sodium dodecyl sulfate-polyacrylamide gel elec-
trophoresis and transferred to a polyvinylidene fluoride
membrane. The membrane was blocked with non-fat skim
milk and incubated with primary antibodies (Abs) against
Erk1/2, p-Erk1/2, p38, p-p38 (1:1000, Cell Signaling),
GluN2A (NR2A) (1:1000, Thermo Scientific), and GluN2B
(NR2B) (1:1000, Millipore), and followed by incubation
with HRP-conjugated secondary Ab (Cell Signaling). The
membranes were visualized using an ECL system and de-
veloped on Hyperfilm (Amersham). The relative expression
levels of all proteins were determined by densitometry and
normalized to actin.
Immunohistochemistry
After the behavioral experiments, 8–9 rats from each
group were euthanized by an overdose of ketamine HCl
(30 mg/kg) and xylazine (2.5 mg/kg). These rats were
then intracardially perfused with 4% paraformaldehyde
(PFA) in 0.01 M phosphate buffer (pH 7.4). After fix-
ation, the brains were removed and postfixed in PFA
(48 h), cryoprotected in phosphate-buffered saline (PBS)
containing 30% sucrose (72 h), frozen on powdered dry
ice, and sectioned (coronal plane: 40 μm) with a micro-
tome. All sections were kept in a cryoprotectant (30%
ethylene glycol, 25% glycerol, 25 mM phosphate buffer)
and stored at −20°C for further use. The monoclonal
antibody anti-OX-6 (1:1000, BD Bioscience) and anti-
Iba-1 Ab (1:1000, Wako) was used to visualize activated
microglial cells and whole microglial cells/macrophage
[21,39]. The expression of Iba-1, a 17-kDa EF-hand pro-
tein, is restricted to microglia/macrophages [21]. For
OX-6 and Iba-1, endogenous peroxidases were blocked by
30 min incubation in 3% H2O2/10% MeOH in PBS. The
sections were incubated for 1 h at room temperature in
PBS with 0.3% Triton-X (PBST) containing 10% fetal
horse serum (GIBCO) and then incubated for further 18 h
at 4°C in the same solution containing the appropriate pri-
mary antibody. Thereafter, sections were incubated for 1 h
in the appropriate biotinylated secondary antibody at
room temperature (1:200), and for 1 h in ExtrAvidin per-
oxidase conjugate (1:1000, Vector Laboratories). They
were then reacted by means of a Vector SG substrate
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mounted onto resin-coated slides, dehydrated through
ascending concentrations of ethanol, defatted in xylene,
and coverslipped with Permount (Fisher).
The Iba-1-positive cells were counted to quantify all
microglial cells. Sections containing the hippocampus
from 4 rats per group were analyzed. For a quantitative
analysis, we selected specific regions in which neuroin-
flammatory changes have been reported in the literature
[40]. The hippocampus, including CA1, CA3, and DG,
was the focus for quantification of microglial activation.
One region of interest (ROI) of 0.03 mm2 per section
in the hippocampal subregions, CA1, CA3, and DG
(bregma −3.00 mm to −4.00 mm; 6 sections per rat) was
selected. The number of Iba-1 microglial cells in each
ROI was counted and averaged. The activated microglia
had characteristic bushy morphologies with increased
cell body size and contracted and ramified processes
[41]. To quantify the activated microglia induced by
chronic LPS infusion, the number of OX-6 positive
microglia within the hippocampi from each rat were
counted in drawings of identical sections.
Double immunofluorescence
The sections were gently washed in PBST for 3 times and
blocked with 5% fetal horse serum diluted in PBST for
1.5 h at room temperature, followed by treatment with a
cocktail of 2 antibodies from anti-p-Erk1/2 (1:300, Cell
Signaling), anti-p-p38 (1:300, Cell Signaling), anti-NeuN
(1:2000, Millipore), anti-CD11b (1:1000, Serotec), and
anti-glial fibrillary acidic protein (GFAP; 1:1000, BD Bio-
science) antibodies for 20 h at room temperature. The sec-
tions were then treated with Alexa® 488-labeled donkey
anti-mouse IgG and Alexa® 568-labeled donkey anti-
rabbit IgG (1:200, Invitrogen) cocktails for 3 h at room
temperature in the dark. Exposure to light was reduced
to minimum after mounting and coverslip, antifade re-
agent (ProLong® Gold, Invitrogen) was used to maintain
fluorescence until microscopy. To assess the pERK and
pp38 expression level in the microglia and astrocyte, the
intensity of pERK and pp38 were measured on a fluores-
cent microscopic picture of 400× magnifications. Region
of interest (ROI) in the hippocampus were drawn along
the CD11b-positive microglia and GFAP-positive astro-
cyte. Intensity of each ROI was measured by Fluoview 10
(Olympus, Japan).
Statistical analysis
ANOVA and one-way repeated ANOVA were conducted
to assess the impairment of spatial memory and the micro-
glial activation (Iba-1- and OX-6-positive cell counts) in-
duced by chronic LPS infusion, and the levels of MAPK
expression (Erk1/2, p-Erk1/2, p38, and p-p38), and the
levels of expression of GluN2A and GluN2B subunits ofNMDARs induced by chronic LPS infusion. P values
less than 0.05 were considered significant, unless other-
wise specified.
Additional file
Additional file 1: Figure S1. Microglial activation in the hippocampi of
aCSF- and LPS-infused rats. (A) Representative photomicrograph of Iba-
1-positive cells in the cornu ammonis 1 (CA1), CA3, and dentate gyrus
(DG) of the hippocampus. (B) The number of hippocampal
Iba-1-positive microglial cells/macrophages was higher in all subfield
areas in the LPS-infused rats (LPS) than in those of the aCSF-infused
rats (aCSF). (C) Representative photomicrograph of OX-6-positive cells
in the hippocampus. (D) The rats with chronic LPS infusion into the 4th
ventricle showed highly activated OX-6-positive microglial cells in the
hippocampal CA3 and DG area compared with that of the rats infused
with aCSF. *, p < 0.05.
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